Last reviewed · How we verify
V116517 30-mg tablets — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
V116517 30-mg tablets (V116517 30-mg tablets) — Purdue Pharma LP.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| V116517 30-mg tablets TARGET | V116517 30-mg tablets | Purdue Pharma LP | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- V116517 30-mg tablets CI watch — RSS
- V116517 30-mg tablets CI watch — Atom
- V116517 30-mg tablets CI watch — JSON
- V116517 30-mg tablets alone — RSS
Cite this brief
Drug Landscape (2026). V116517 30-mg tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/v116517-30-mg-tablets. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab